Israelis receive a dose of the Pfizer-BioNTech coronavirus vaccine at a hospital in Rishon Lezion on August 13, 2021 at the start of the country's booster campaign. (Photo: Ahmad Gharabli/AFP via Getty Images)
As Biden Pushes Boosters Amid Global Vaccine Inequality, Departing FDA Officials Speak Out
"Even if some gain can ultimately be obtained from boosting, it will not outweigh the benefits of providing initial protection to the unvaccinated."
As public health advocates warn that Covid-19 boosters could exacerbate deadly consequences of global vaccine inequality, two leading vaccination officials at the U.S. Food and Drug Administration were part of an international group of medical experts who said Monday that most people don't require such shots at this time.
"If vaccines are deployed where they would do the most good, they could hasten the end of the pandemic by inhibiting further evolution of variants."
--Public health experts
The experts' joint opposition to boosters, as The Hill reported, comes as the Biden administration "is pushing for boosters to be widely available to all Americans beginning September 20, despite disagreement from outside scientists and some health agency officials who argue it's premature, and that the data are not strong enough to support such a move."
In an editorial (pdf) published in the U.K.-based medical journal The Lancet, the experts--who include Food and Drug Administration (FDA) vaccine reviewers Drs. Phil Krause and Marion Gruber--note that Covid-19 vaccines "continue to be effective against severe disease, including that caused by the Delta variant."
Krause and Gruber, both longtime FDA employees, recently said they will be leaving the agency later this fall, without providing reasons for their departure.
The authors acknowledge that "boosting could be appropriate for some individuals in whom the primary vaccination... might not have induced adequate protection," including people who are immunocompromised.
However, they point out that "there could be risks if boosters are widely introduced too soon, or too frequently, especially with vaccines that can have immune-mediated side effects," and that "significant adverse reactions" could have "implications for vaccine acceptance that go beyond Covid-19 vaccines."
"Thus, widespread boosting should be undertaken only if there is clear evidence that it is appropriate," the editorial states.
Addressing the issue of vaccine inequality, the experts write:
The limited supply of these vaccines will save the most lives if made available to people who are at appreciable risk of serious disease and have not yet received any vaccine. Even if some gain can ultimately be obtained from boosting, it will not outweigh the benefits of providing initial protection to the unvaccinated.
If vaccines are deployed where they would do the most good, they could hasten the end of the pandemic by inhibiting further evolution of variants. Indeed, [the World Health Organization] has called for a moratorium on boosting until the benefits of primary vaccination have been made available to more people around the world.
This is a compelling issue, particularly as the currently available evidence does not show the need for widespread use of booster vaccination in populations that have received an effective primary vaccination regimen.
Last week, WHO Director-General Dr. Tedros Adhanom Ghebreyesus said he was "appalled" that wealthy nations, including the United States, are moving ahead with plans to administer booster shots, even as billions of people around the world still have not received even a single dose of the vaccine. According to Our World in Data, less than 2% of people in low-income countries have been fully vaccinated against the coronavirus.
The Lancet editorial was published as wealthy nations face increasing pressure to support temporarily waiving patent protections on vaccines to allow for their widespread production and distribution. More than 100 nations support a World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property (TRIPS) waiver, first proposed by India and South Africa. However, to date, the only wealthy nations backing the proposal are the United States, France, and Australia.
Last week, WHO Regional Director for Africa Dr. Matshidiso Moeti partially blamed the rollout of booster shots in rich countries for a projected 25% shortfall in vaccine deliveries to Africa by the end of the year.
The WTO TRIPS Council is scheduled to convene an informal meeting on Tuesday.
Urgent. It's never been this bad.
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission from the outset was simple. To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It’s never been this bad out there. And it’s never been this hard to keep us going. At the very moment Common Dreams is most needed and doing some of its best and most important work, the threats we face are intensifying. Right now, with just two days to go in our Spring Campaign, we're falling short of our make-or-break goal. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Can you make a gift right now to make sure Common Dreams not only survives but thrives? There is no backup plan or rainy day fund. There is only you. —Craig Brown, Co-founder |
As public health advocates warn that Covid-19 boosters could exacerbate deadly consequences of global vaccine inequality, two leading vaccination officials at the U.S. Food and Drug Administration were part of an international group of medical experts who said Monday that most people don't require such shots at this time.
"If vaccines are deployed where they would do the most good, they could hasten the end of the pandemic by inhibiting further evolution of variants."
--Public health experts
The experts' joint opposition to boosters, as The Hill reported, comes as the Biden administration "is pushing for boosters to be widely available to all Americans beginning September 20, despite disagreement from outside scientists and some health agency officials who argue it's premature, and that the data are not strong enough to support such a move."
In an editorial (pdf) published in the U.K.-based medical journal The Lancet, the experts--who include Food and Drug Administration (FDA) vaccine reviewers Drs. Phil Krause and Marion Gruber--note that Covid-19 vaccines "continue to be effective against severe disease, including that caused by the Delta variant."
Krause and Gruber, both longtime FDA employees, recently said they will be leaving the agency later this fall, without providing reasons for their departure.
The authors acknowledge that "boosting could be appropriate for some individuals in whom the primary vaccination... might not have induced adequate protection," including people who are immunocompromised.
However, they point out that "there could be risks if boosters are widely introduced too soon, or too frequently, especially with vaccines that can have immune-mediated side effects," and that "significant adverse reactions" could have "implications for vaccine acceptance that go beyond Covid-19 vaccines."
"Thus, widespread boosting should be undertaken only if there is clear evidence that it is appropriate," the editorial states.
Addressing the issue of vaccine inequality, the experts write:
The limited supply of these vaccines will save the most lives if made available to people who are at appreciable risk of serious disease and have not yet received any vaccine. Even if some gain can ultimately be obtained from boosting, it will not outweigh the benefits of providing initial protection to the unvaccinated.
If vaccines are deployed where they would do the most good, they could hasten the end of the pandemic by inhibiting further evolution of variants. Indeed, [the World Health Organization] has called for a moratorium on boosting until the benefits of primary vaccination have been made available to more people around the world.
This is a compelling issue, particularly as the currently available evidence does not show the need for widespread use of booster vaccination in populations that have received an effective primary vaccination regimen.
Last week, WHO Director-General Dr. Tedros Adhanom Ghebreyesus said he was "appalled" that wealthy nations, including the United States, are moving ahead with plans to administer booster shots, even as billions of people around the world still have not received even a single dose of the vaccine. According to Our World in Data, less than 2% of people in low-income countries have been fully vaccinated against the coronavirus.
The Lancet editorial was published as wealthy nations face increasing pressure to support temporarily waiving patent protections on vaccines to allow for their widespread production and distribution. More than 100 nations support a World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property (TRIPS) waiver, first proposed by India and South Africa. However, to date, the only wealthy nations backing the proposal are the United States, France, and Australia.
Last week, WHO Regional Director for Africa Dr. Matshidiso Moeti partially blamed the rollout of booster shots in rich countries for a projected 25% shortfall in vaccine deliveries to Africa by the end of the year.
The WTO TRIPS Council is scheduled to convene an informal meeting on Tuesday.
As public health advocates warn that Covid-19 boosters could exacerbate deadly consequences of global vaccine inequality, two leading vaccination officials at the U.S. Food and Drug Administration were part of an international group of medical experts who said Monday that most people don't require such shots at this time.
"If vaccines are deployed where they would do the most good, they could hasten the end of the pandemic by inhibiting further evolution of variants."
--Public health experts
The experts' joint opposition to boosters, as The Hill reported, comes as the Biden administration "is pushing for boosters to be widely available to all Americans beginning September 20, despite disagreement from outside scientists and some health agency officials who argue it's premature, and that the data are not strong enough to support such a move."
In an editorial (pdf) published in the U.K.-based medical journal The Lancet, the experts--who include Food and Drug Administration (FDA) vaccine reviewers Drs. Phil Krause and Marion Gruber--note that Covid-19 vaccines "continue to be effective against severe disease, including that caused by the Delta variant."
Krause and Gruber, both longtime FDA employees, recently said they will be leaving the agency later this fall, without providing reasons for their departure.
The authors acknowledge that "boosting could be appropriate for some individuals in whom the primary vaccination... might not have induced adequate protection," including people who are immunocompromised.
However, they point out that "there could be risks if boosters are widely introduced too soon, or too frequently, especially with vaccines that can have immune-mediated side effects," and that "significant adverse reactions" could have "implications for vaccine acceptance that go beyond Covid-19 vaccines."
"Thus, widespread boosting should be undertaken only if there is clear evidence that it is appropriate," the editorial states.
Addressing the issue of vaccine inequality, the experts write:
The limited supply of these vaccines will save the most lives if made available to people who are at appreciable risk of serious disease and have not yet received any vaccine. Even if some gain can ultimately be obtained from boosting, it will not outweigh the benefits of providing initial protection to the unvaccinated.
If vaccines are deployed where they would do the most good, they could hasten the end of the pandemic by inhibiting further evolution of variants. Indeed, [the World Health Organization] has called for a moratorium on boosting until the benefits of primary vaccination have been made available to more people around the world.
This is a compelling issue, particularly as the currently available evidence does not show the need for widespread use of booster vaccination in populations that have received an effective primary vaccination regimen.
Last week, WHO Director-General Dr. Tedros Adhanom Ghebreyesus said he was "appalled" that wealthy nations, including the United States, are moving ahead with plans to administer booster shots, even as billions of people around the world still have not received even a single dose of the vaccine. According to Our World in Data, less than 2% of people in low-income countries have been fully vaccinated against the coronavirus.
The Lancet editorial was published as wealthy nations face increasing pressure to support temporarily waiving patent protections on vaccines to allow for their widespread production and distribution. More than 100 nations support a World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property (TRIPS) waiver, first proposed by India and South Africa. However, to date, the only wealthy nations backing the proposal are the United States, France, and Australia.
Last week, WHO Regional Director for Africa Dr. Matshidiso Moeti partially blamed the rollout of booster shots in rich countries for a projected 25% shortfall in vaccine deliveries to Africa by the end of the year.
The WTO TRIPS Council is scheduled to convene an informal meeting on Tuesday.